Pharming Group N.V. Retained Earnings 2011-2026 | PHAR

Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.

Possible uses include

reinvestment in development (R&D, equipment, marketing)
debt repayment
acquisition of other companies
creation of reserves for the future

A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.

The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.

Annual Retained Earnings Pharming Group N.V.

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-	-257 M	-298 M	-334 M	-356 M	-279 M	-264 M	-257 M	-268 M	-264 M	-258 M

All numbers in EUR currency

Indicator range from annual reports

Maximum	Minimum	Average
-257 M	-356 M	-283 M

Quarterly Retained Earnings Pharming Group N.V.

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	-	-258 M	-	-	-	-298 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in EUR currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-258 M	-298 M	-278 M

Retained Earnings of other stocks in the Biotechnology industry

Issuer	Retained Earnings	Price	% 24h	Market Cap	Country
BioNTech SE BNTX	-410 M	$ 91.28	0.11 %	$ 27.2 B	Germany
MorphoSys AG MOR	-158 M	-	2.43 %	$ 254 M	Germany
I-Mab IMAB	-8.33 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	5.24 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	-405 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	-17.1 M	-	-13.47 %	$ 169 M	France
Midatech Pharma plc MTP	-122 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	-108 M	-	-1.52 %	$ 24.7 M	USA
Acorda Therapeutics ACOR	-1.19 B	-	-24.86 %	$ 820 K	USA
Advaxis ADXS	-197 M	-	-9.65 %	$ 45.9 M	USA
Adverum Biotechnologies ADVM	-1.07 B	-	-	$ 86.2 M	USA
Институт стволовых клеток человека ISKJ	69.4 M	-	-	-	Russia
Aeterna Zentaris AEZS	-335 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	-63.5 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	-1.13 B	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	-308 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	-268 M	-	1.93 %	$ 17.4 M	USA
Aptose Biosciences APTO	-566 M	-	-45.71 %	$ 1.2 M	Canada
Akero Therapeutics AKRO	-826 M	-	-	$ 3.67 B	USA
CureVac N.V. CVAC	-1.06 B	-	-	$ 867 M	Germany
Akari Therapeutics, Plc AKTX	-265 M	$ 3.54	-20.81 %	$ 238 B	Britain
Akouos AKUS	-168 M	-	0.23 %	$ 488 M	USA
Allakos ALLK	-1.12 B	-	-	$ 28.6 M	USA
Allena Pharmaceuticals ALNA	-246 M	-	3.16 %	$ 1.9 M	USA
Alnylam Pharmaceuticals ALNY	-6.7 B	$ 330.34	3.6 %	$ 43.3 B	USA
Alpine Immune Sciences ALPN	-224 M	-	-	$ 2.17 B	USA
Aileron Therapeutics ALRN	-401 M	-	10.36 %	$ 9.8 M	USA
AlloVir ALVR	-160 M	-	4.14 %	$ 49.1 M	USA
Evogene Ltd. EVGN	-179 M	$ 0.79	1.22 %	$ 27.9 M	Israel
Atreca BCEL	-457 M	-	-11.76 %	$ 5.79 M	USA
Ampio Pharmaceuticals AMPE	-243 M	-	-11.43 %	$ 502 K	USA
argenx SE ARGX	-861 M	$ 748.25	0.25 %	$ 25 B	Niderland
Завод ДИОД DIOD	1.21 B	-	-	-	Russia
Фармсинтез LIFE	-3.54 B	-	-	-	Russia
Applied Molecular Transport AMTI	-366 M	-	-	$ 10.1 M	USA
Aptorum Group Limited APM	-72.4 M	$ 0.89	-4.33 %	$ 4.85 M	China
Applied Therapeutics APLT	-469 M	-	-	$ 8.42 M	USA
Aptinyx APTX	-353 M	-	-39.0 %	$ 4.57 M	USA
Teligent, Inc. TLGT	-121 M	-	-13.85 %	$ 16.1 M	USA
AbbVie ABBV	-15.5 B	$ 206.69	-1.01 %	$ 366 B	USA
Aquestive Therapeutics AQST	-447 M	$ 4.09	-0.97 %	$ 437 M	USA
Aravive ARAV	-616 M	-	-13.39 %	$ 1.45 M	USA
Viela Bio, Inc. VIE	-427 M	-	-	$ 2.91 B	USA
AbCellera Biologics ABCL	-29.5 M	$ 3.39	-3.69 %	$ 1.01 B	Canada
Arcturus Therapeutics Holdings ARCT	-515 M	$ 8.22	2.37 %	$ 225 M	Israel
Ardelyx ARDX	-947 M	$ 5.97	0.51 %	$ 1.44 B	USA
Genmab A/S GMAB	7.11 B	$ 27.75	0.91 %	$ 17.6 B	Danmark
Cerevel Therapeutics Holdings CERE	-1.4 B	-	-	$ 7.29 B	USA
Grifols, S.A. GRFS	619 M	$ 8.23	-0.12 %	$ 6.83 B	Spain
Akebia Therapeutics AKBA	-1.68 B	$ 1.32	-4.35 %	$ 339 M	USA